Short Interest in BioHarvest Sciences Inc. (NASDAQ:BHST) Decreases By 52.9%

BioHarvest Sciences Inc. (NASDAQ:BHST) saw a large drop in short interest during the month of December. As of December 15th, there was short interest totaling 33,198 shares, a drop of 52.9% from the November 30th total of 70,472 shares. Based on an average daily volume of 64,612 shares, the days-to-cover ratio is currently 0.5 days. Approximately 0.2% of the shares of the company are sold short. Approximately 0.2% of the shares of the company are sold short. Based on an average daily volume of 64,612 shares, the days-to-cover ratio is currently 0.5 days.

BioHarvest Sciences Stock Performance

BHST traded down $0.28 during trading hours on Friday, hitting $5.33. The company’s stock had a trading volume of 28,864 shares, compared to its average volume of 59,806. The company has a 50-day simple moving average of $7.29 and a 200 day simple moving average of $8.02. The firm has a market capitalization of $87.52 million, a PE ratio of -7.84 and a beta of 0.95. BioHarvest Sciences has a fifty-two week low of $4.72 and a fifty-two week high of $12.80. The company has a current ratio of 1.35, a quick ratio of 1.02 and a debt-to-equity ratio of 0.30.

BioHarvest Sciences (NASDAQ:BHST) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.14) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.14). BioHarvest Sciences had a negative net margin of 36.33% and a negative return on equity of 1,041.86%. The company had revenue of $9.07 million for the quarter, compared to analysts’ expectations of $9.11 million. As a group, sell-side analysts expect that BioHarvest Sciences will post -0.8 EPS for the current year.

Hedge Funds Weigh In On BioHarvest Sciences

An institutional investor recently raised its position in BioHarvest Sciences stock. True North Advisors LLC lifted its position in BioHarvest Sciences Inc. (NASDAQ:BHST) by 676.1% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 168,013 shares of the company’s stock after purchasing an additional 146,365 shares during the quarter. True North Advisors LLC owned 1.02% of BioHarvest Sciences worth $1,581,000 at the end of the most recent reporting period.

Wall Street Analyst Weigh In

Several brokerages have weighed in on BHST. Wall Street Zen upgraded shares of BioHarvest Sciences to a “hold” rating in a research report on Saturday, October 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioHarvest Sciences in a report on Monday. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, BioHarvest Sciences presently has an average rating of “Hold” and a consensus target price of $14.50.

About BioHarvest Sciences

BioHarvest Sciences Inc is a biotechnology company that specializes in the development and commercialization of plant-based active ingredients through proprietary cell-culture technology. By growing undifferentiated plant cells in controlled bioreactor environments, the company aims to produce full-spectrum phytonutrients and botanical compounds that are difficult to obtain through traditional farming methods. This approach is designed to deliver consistent, high-purity extracts with reduced environmental impact and supply-chain variability.

The company’s product portfolio focuses on applications across the cosmeceutical, nutraceutical and health-and-wellness markets.